Effect of cyclosporine A on the binding affinity and internalization of low-density lipoproteins in human skin fibroblasts

Journal of Pharmaceutical Sciences

Volumn 91, Issue 12, 2002, Pages 2520-2524

  Wasan, Kishor M ^a   Donnachie, Elizabeth M ^a   Seccombe, David W ^a   Pritchard, P Haydn ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Cyclosporine A; Human skin fibroblasts; Low density lipoprotein receptors

Indexed keywords

CYCLOSPORIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; CYCLOSPORIN;

BINDING AFFINITY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; IMMUNOSUPPRESSIVE TREATMENT; INTERNALIZATION; ISOTOPE LABELING; ORGAN TRANSPLANTATION; RECEPTOR AFFINITY; RECEPTOR BINDING; SKIN FIBROBLAST; ARTICLE; CYTOLOGY; FIBROBLAST; METABOLISM; PHYSIOLOGY; PROTEIN BINDING; SKIN;

CYCLOSPORINE; FIBROBLASTS; HUMANS; LIPOPROTEINS, LDL; PROTEIN BINDING; SKIN;

EID: 0036893244     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10249     Document Type: Conference Paper

References (28)

1. Keown PA. 1990. Emerging indications for the use of cyclosporin in organ transplantation and auto-immunity. Drugs 40:315-325.
2. Wong RL, Winslow CM, Cooper KD. 1993. The mechanisms of action of cyclosporin A in the treatment of psoriasis. Immunol Today 14:69-74.
3. Bennett WM. 1990. Renal effects of cyclosporine. J Am Acad Dermatol 23:1280-1287.
4. Mihatsch MJ, Ryffel B, Gudat F. 1995. The differential diagnosis between rejection and cyclosporine toxicity. Kidney Int 48 Suppl 52:S63-S69.
5. Zimmerhackl LB, Mesa H, Kramer F, Kolmel C, Wiegele G, Brandis M. 1997. Tubular toxicity of cyclosporine A and the influence of endothelin-1 in renal cell culture models (LLC-PK1 and MDCK). Pediatr Nephrol 11:778-783.
6. Healy E, Dempsey M, Lally C, Ryan MP. 1998. Apoptosis and necrosis: Mechanisms of cell death induced by cyclosporine A in a renal proximal tubular cell line. Kidney Int 54:1955-1966.
7. Cole E, Cheung F, Wong PY, Fung LS, Skorecki K, Levy GA. 1989. Toxic effects on renal cells in culture - A comparison of cyclosporin A and its metabolites. Transplantation Proc 21:943-945.
8. Walker RJ, Lazzaro VA, Duggin GG, Horvath JS, Tiller DJ. 1989. Structure-activity relationships of cyclosporines. Toxicity in cultured renal tubular epithelial cells. Transplantation 48:321-327.
9. John GT, Dakshinamurthy DS, Jeyaseelan L, Jacob CK. 1999. The effect of cyclosporin A on plasma lipids during the first year after renal transplantation. Natl Med J India 12:14-17.
10. Edwards BD, Bhatnagar D, Mackness MI, Gokal R, Ballardie FW, Chalmers RJ, Durrington PN. 1995. Effect of low-dose cyclosporin on plasma lipoproteins and markers of cholestasis in patients with psoriasis. QJM 88:109-113.
11. Lopez-Miranda J, Vilella E, Perez-Jiminez F, Espino A, Jimenez-Pereperez JA, Masano L, Turner PR. 1993. Low-density lipoprotein metabolism in rats treated with cyclosporine. Metabolism 42:678-683.
12. Brown MS, Goldstein JL. 1986. A receptor-mediated pathway for cholesterol homeostasis. Science 232:34-44.
13. Verril HL, Girgis RE, Easterling RE, Malhi BS, Mueller WF. 1987. Distribution of cylcosporin in blood of a renal-transplant recipient with Type V Hyperlipoproteinemia. Clin Chem 33:423-428.
14. Lemaire M, Tillement JP. 1982. Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood. J Pharm Pharmacol 34:715-718.
15. Havel RJ, Eder HA, Bragdon JH. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34:1345-1353.
16. Noble RP. 1968. Electrophoretic separation of plasma lipoproteins in agarose gel. J Lipid Res 9:693-700.
17. Lowry OH, Rosenbrough NJ, Farr AL, Randall RL. 1951. Protein measurement with the folin phenol reagent. J Biol Chem 193:265-275.
18. McFarlane AS. 1958. Efficient trace-labelling of proteins with iodine. Nature 4627:53.
19. Goldstein JL, Basu SK, Brown MS. 1983. Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. Methods Enzymol 98:241-260.
20. Myant NB. 1990. Cholesterol Metabolism, LDL and the LDL Receptor. Toronto, Ontario, Canada: Academic, pp. 201-220.
21. Snyder ML, Hay RV, Whitington PF, Scanu AM, Fless GM. 1994. Binding and degradation of lipoprotein(a) and LDL by primary cultures of human hepatocytes. Arterioscler Thromb 14:770-779.
22. Matthews JC. 1993. Fundamentals of Receptor, Enzyme and Transport Kinetics. Boca Raton, FL: CRC Press, pp. 65-80.
23. Motulsky HJ, Ransnas LA. 1987. Fitting curves to data using non-linear regression: A practical and nonmathematical review. FASEB J 1:365-374.
24. Goldstein JL, Brown MS. 1974. Binding and degradation of LDL by cultured fibroblasts. J Biol Chem 249:5153-5162.
25. Goldstein JL, Brown MS. 1974. Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozy gous familial hypercholesterolemia. J Biol Chem 249:5153-5162.
26. Sanghvi A, Warty V, Zeevi A, Diven W, Duquesnoy R, Makowka L, Starzl TE. 1987. FK-506 enhances cyclosporine uptake by periferal blood lymphocytes. Transplant Proc 19:45-49.
27. Kataoka M, Shimizu Y, Kunikiyo K, Asahara Y, Yamashita K, Ninomiya M, Morisaki I, Ohsaki Y, Kido JI, Nagata T. 2000. Cyclosporin A decreases the degradation of type I collagen in rat gingival overgrowth. J Cell Physiol 182:351-358.
28. Arora PD, Silvestri L, Ganss B, Sodek J, McCulloch CA. 2001. Mechanism of cyclosporin-induced inhibition of intracellular collagen degradation. J Biol Chem 276:14100-14109.